Syneos Health (NASDAQ:SYNH) had its price target lifted by KeyCorp from $65.00 to $71.00 in a report released on Thursday, The Fly reports. KeyCorp currently has an overweight rating on the stock. KeyCorp also issued estimates for Syneos Health’s Q4 2019 earnings at $0.88 EPS, FY2019 earnings at $2.80 EPS and FY2020 earnings at $3.26 EPS.

A number of other brokerages also recently weighed in on SYNH. ValuEngine raised Syneos Health from a sell rating to a hold rating in a research report on Tuesday. Citigroup assumed coverage on Syneos Health in a research report on Monday, January 6th. They set a buy rating and a $75.00 price objective on the stock. Finally, Jefferies Financial Group raised their price objective on Syneos Health from $62.00 to $65.00 and gave the company a buy rating in a research report on Monday, September 23rd. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Syneos Health currently has a consensus rating of Buy and an average price target of $63.44.

SYNH stock traded up $0.13 during trading on Thursday, reaching $63.99. 343,314 shares of the company traded hands, compared to its average volume of 503,116. Syneos Health has a 12 month low of $36.72 and a 12 month high of $64.72. The business has a 50 day simple moving average of $58.04 and a 200 day simple moving average of $53.29. The company has a market capitalization of $6.63 billion, a price-to-earnings ratio of 24.42, a price-to-earnings-growth ratio of 1.79 and a beta of 1.52. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.03 and a current ratio of 1.03.

Syneos Health (NASDAQ:SYNH) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.05. Syneos Health had a return on equity of 10.13% and a net margin of 1.86%. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the company earned $0.75 earnings per share. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. As a group, research analysts forecast that Syneos Health will post 2.81 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Pictet Asset Management Ltd. raised its stake in Syneos Health by 10.0% in the third quarter. Pictet Asset Management Ltd. now owns 686,566 shares of the company’s stock valued at $36,532,000 after buying an additional 62,300 shares during the last quarter. California Public Employees Retirement System raised its stake in Syneos Health by 9.9% in the third quarter. California Public Employees Retirement System now owns 116,925 shares of the company’s stock valued at $6,222,000 after buying an additional 10,542 shares during the last quarter. New York State Teachers Retirement System raised its stake in Syneos Health by 54.3% in the third quarter. New York State Teachers Retirement System now owns 19,600 shares of the company’s stock valued at $1,043,000 after buying an additional 6,900 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Syneos Health by 5.1% in the third quarter. Russell Investments Group Ltd. now owns 153,503 shares of the company’s stock valued at $8,168,000 after buying an additional 7,497 shares during the last quarter. Finally, Parametric Portfolio Associates LLC raised its stake in Syneos Health by 18.8% in the second quarter. Parametric Portfolio Associates LLC now owns 301,841 shares of the company’s stock valued at $15,421,000 after buying an additional 47,822 shares during the last quarter.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

See Also: How to build a Fibonacci channel

The Fly

Analyst Recommendations for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.